iCAD to highlight research on potential of its ProFound AI Risk algorithm

iCAD announced it will highlight new research demonstrating the efficacy of its ProFound AI Risk algorithm in breast cancer risk assessment compared to traditional models at the upcoming Society for Imaging Informatics in Medicine, SIIM, Annual Meeting. The company will also highlight its recently launched ProFound Cloud, an advanced software-as-a-service, SaaS, platform that offers medical providers a cost-effective, secure, and scalable solution for accessing and deploying the latest ProFound Breast Health Suite of AI solutions. “Dr. Traill’s latest research is a significant step forward in the application of iCAD‘s ProFound AI Risk for breast cancer risk assessment. The ability to identify women with a higher likelihood of breast cancer by analyzing changes in AI-derived risk score between a woman’s prior and current mammogram will facilitate earlier intervention and improve outcomes,” said Dana Brown, president and CEO of iCAD.